Compare Schwab US Large Cap Growth ETF (SCHG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Schwab US Large Cap Growth ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Schwab US Large Cap Growth ETF trades at $36.74 (market cap $65.01B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Schwab US Large Cap Growth ETF is far larger — about 6.4× State Street SPDR S&P Biotech ETF's market cap, and Schwab US Large Cap Growth ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Schwab US Large Cap Growth ETF for 50 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| SCHG | XBI | |
|---|---|---|
Market Cap | $65.01B | $10.11B |
Volume | 8,554,399 | 12,903,266 |
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $36.93 | $169.55 |
52-Week Low | $28.10 | $104.99 |
Typical Hold Time | 50 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SCHG (Schwab U.S. Large-Cap Growth ETF) trades at $36.42, down 1.22% with a bullish technical signal from moving averages. The ETF focuses on large-cap growth stocks with heavy concentration in top holdings like Apple. Recent news highlights SCHG's long-term growth potential and tax-efficient characteristics for retirement planning.
SCHG offers exposure to quality growth companies at a low 0.03% expense ratio, but faces concentration risk in top holdings. The ETF's performance depends heavily on megacap tech stocks, making it vulnerable to sector rotations. Long-term growth prospects remain strong based on historical performance.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
